Does the 505(b)(2) Regulatory Pathway for NDA's Provide an Adequate ROI?

I have a post on LinkedIn where I share a few thoughts about the benefits and limitations of developing drugs using the 505(b)(2) regulatory pathway. Hardly a week goes by without a pharmaceutical company expressing the desire to reap the benefits of developing a drug using the “505(b)(2) regulatory pathway”. What are 505(b)(2) new drug applications (NDAs) and do they really provide a meaningful advantage to pharmaceutical companies?

For the full post on LinkedIn, please see: http://tinyurl.com/j9fh2zn

 

Be the first to comment

Please check your e-mail for a link to activate your SDEE account.

Attend SDEE Events Donate | Sponsor SDEE Become a Member

Connect with SDEE

Sign Up for SDEE Newsletter


SDEE GOLD SPONSORS

Takeda San Diego

SDEE SILVER SPONSORS

Barney and Barney TriNet

SDEE BRONZE SPONSORS

Knobe Martens Duane Morris MaxCyte

SDEE is a nonprofit 501(c)(3) organization founded by local San Diego entrepreneurs
in order to provide a voice for the early stage start-up, to support new entrepreneurs and their companies,
and to sponsor networking and educational events
to help develop the skills necessary to bring funding, business, and jobs to the San Diego area.

© 2015 San Diego Entrepreneurs Exchange. All Rights Reserved